Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 5.4% – Should You Sell?

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) were down 5.4% during trading on Thursday . The company traded as low as $4.22 and last traded at $4.2950. Approximately 1,430,545 shares changed hands during trading, a decline of 88% from the average daily volume of 12,357,262 shares. The stock had previously closed at $4.54.

Wall Street Analyst Weigh In

IRWD has been the subject of a number of recent research reports. Citigroup upgraded shares of Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, January 5th. Zacks Research raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 1st. Citizens Jmp raised Ironwood Pharmaceuticals from a “market perform” rating to a “market outperform” rating and set a $8.00 target price for the company in a report on Monday, January 5th. Weiss Ratings reiterated a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, December 29th. Finally, Craig Hallum upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 5th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $6.12.

Ironwood Pharmaceuticals Stock Performance

The stock has a market cap of $736.12 million, a P/E ratio of 28.22 and a beta of 0.18. The stock has a 50-day moving average price of $3.47 and a 200-day moving average price of $1.99.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.15. The company had revenue of $122.06 million for the quarter, compared to analysts’ expectations of $74.22 million. Ironwood Pharmaceuticals had a net margin of 8.70% and a negative return on equity of 15.17%. Sell-side analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in IRWD. OVERSEA CHINESE BANKING Corp Ltd purchased a new position in shares of Ironwood Pharmaceuticals in the 2nd quarter worth about $25,000. Integrated Wealth Concepts LLC grew its position in Ironwood Pharmaceuticals by 21.4% during the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 3,406 shares during the last quarter. R Squared Ltd grew its position in Ironwood Pharmaceuticals by 286.5% during the second quarter. R Squared Ltd now owns 38,765 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 28,735 shares during the last quarter. Focus Partners Advisor Solutions LLC raised its stake in shares of Ironwood Pharmaceuticals by 284.6% during the second quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 29,409 shares in the last quarter. Finally, Captrust Financial Advisors bought a new stake in shares of Ironwood Pharmaceuticals in the 2nd quarter worth approximately $32,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.